|
業務類別
|
Biotechnology |
|
業務概覽
|
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535. |
| 公司地址
| One Main Street, 14th Floor, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 617 252-0848 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.blackdiamondtherapeutics.com |
| 員工數量
| 24 |
| Mr. Brent Hatzis-Schoch, Esq. |
Chief Operating Officer and General Counsel |
美元 493.70K |
18/04/2025 |
| Dr. Mark A. Velleca, M.D. |
Chairman of the Board, President and Chief Executive Officer |
美元 644.80K |
18/04/2025 |
| Ms. Elizabeth Buck, PhD |
Chief Scientific Officer |
-- |
18/04/2025 |
| Ms. Melanie Morrison |
Chief Development Officer |
-- |
18/04/2025 |
| Ms. Erika Jones |
Senior Vice President, Finance, Principal Financial Officer and Principal Accounting Officer |
-- |
18/04/2025 |
| Mr. Sergey Yurasov, M.D.,Pd.D |
Chief Medical Officer |
美元 507.80K |
18/04/2025 |
|
|
| Dr. Kapil Dhingra, M.B.B.S. |
Independent Director |
18/04/2025 |
| Dr. Garry E. Menzel, PhD |
Independent Director |
18/04/2025 |
| Dr. Ali Behbahani, M.B.A.,M.D. |
Independent Director |
18/04/2025 |
| Dr. Samarth Kulkarni, PhD |
Lead Independent Director |
18/04/2025 |
| Dr. Mark A. Velleca, M.D. |
Chairman of the Board, President and Chief Executive Officer |
18/04/2025 |
| Dr. Prakash Raman, PhD |
Independent Director |
18/04/2025 |
| Ms. Shannon Campbell, PhD |
Independent Director |
18/04/2025 |
|
|
|
|
